What is Zacks Research's Forecast for TEVA Q2 Earnings?

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Analysts at Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for shares of Teva Pharmaceutical Industries in a research note issued on Wednesday, May 28th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.62 per share for the quarter, up from their prior forecast of $0.61. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q4 2026 earnings at $0.68 EPS.

A number of other equities research analysts have also recently weighed in on TEVA. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $21.00 to $23.00 in a report on Monday, May 12th. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target on the stock. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Bank of America boosted their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $24.50.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded up $0.04 on Friday, hitting $17.30. 3,094,483 shares of the company's stock were exchanged, compared to its average volume of 10,076,693. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The firm's 50-day moving average price is $15.55 and its two-hundred day moving average price is $17.38. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The firm has a market cap of $19.62 billion, a price-to-earnings ratio of -11.93, a P/E/G ratio of 1.44 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The firm's revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.48 EPS.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently bought and sold shares of the business. FMR LLC lifted its holdings in Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares during the last quarter. Ion Asset Management Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock valued at $599,945,000 after buying an additional 2,383,500 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after buying an additional 4,418,961 shares during the last quarter. Menora Mivtachim Holdings LTD. raised its holdings in shares of Teva Pharmaceutical Industries by 2.8% during the first quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company's stock valued at $448,640,000 after buying an additional 808,074 shares during the last quarter. Finally, Lingotto Investment Management LLP raised its holdings in shares of Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock valued at $599,320,000 after buying an additional 688,862 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.